Hematologic Oncology

Jennifer R. Brown, MD, PhD, and John Byrd, MD, are leading researchers in the emerging field of Bruton tyrosine kinase (BTK) inhibition in chronic lymphocytic leukemia (CLL) and other B-cell malignancies.

Farhad Ravandi, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance in adults with acute myeloid leukemia.

A greater understanding of the molecular mechanisms underlying lymphoid malignancies has fostered the development of targeted therapies, including those aimed at B-cell signaling pathways.

Ari Melnick, MD, professor of medicine, Weill Cornell Medical College, discusses the association between epigenetic diversity and clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL).

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the challenges of treating patients with Hodgkin's lymphoma.

Treatment with the oral PI3K-delta inhibitor idelalisib produced an overall response rate of 57% with an average response duration of 12.5 months in heavily pretreated patients with indolent non-Hodgkin's lymphoma.

Harry Erba, MD, PhD, discusses the frequency in which patients with chronic-phase chronic myeloid leukemia (CML) fail to achieve a BCR-ABL transcript level below 10% after 3 months of treatment with imatinib.

Vemurafenib (Zelboraf), a BRAF inhibitor approved to treat melanoma, induced a complete clinical remission in a patient with hairy cell leukemia.

Mark R. Litzow. MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses ways of conducting minimal residual disease (MRD) assessments in patients with acute lymphoblastic leukemia

Adrienne Phillips, MD, MPH, assistant professor of clinical medicine, Columbia University Medical Center, discusses advances in the treatment of HTLV-related adult T-cell leukemia lymphoma.

A crop of targeted agents have demonstrated promising results in fighting chronic lymphocytic leukemia (CLL), suggesting that a range of emerging therapies and drug combinations may be more effective and better tolerated than standard chemotherapy

During his undergraduate years at Princeton University, Charles L. Sawyers, MD, studied history. Now, well into his career as a physician and translational scientist, Sawyers is busy making it.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses clinical responses in patients with chronic lymphoblastic leukemia (CLL) or acute lymphoblastic leukemia (ALL) following infusion with CD19-targeted T Cells.